Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma.
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma.
复制标题
DOI：
10.1186/s40364-016-0064-5
复制
发表时间：
2016
影响因子：
11.1
通讯作者：
Johnsson A
中科院分区：
文献类型：
--
作者：
Borg D;Hedner C;Gaber A;Nodin B;Fristedt R;Jirström K;Eberhard J;Johnsson A
关于 IFITM1（干扰素诱导跨膜蛋白 1）在各种恶性肿瘤中的报道越来越多。本研究的目的是检测 IFITM1 在胃食管腺癌中的表达及其预后意义。组织样本取自 2006 年至 2010 年间接受手术治疗的 174 名胃食管（胃、胃食管交界处和食管）腺癌患者的连续队列，未接受新辅助治疗。使用免疫组织化学对原发性肿瘤的组织微阵列以及邻近正常上皮、肠化生和淋巴结转移的配对样本检查 IFITM1 的表达。与邻近正常上皮和肠化生相比，无论肿瘤位置如何，IFITM1 的表达在原发性肿瘤和淋巴结转移中显着升高。 IFITM1 的过度表达与 M0 疾病（无远处转移）相关。在胃癌中，在 Kaplan-Meier 分析和 Cox 回归中，在未调整分析（HR 0.33，95% CI 0.12-0.88）和调整分析（HR 0.32，95% CI 0.12-0.87）中，IFITM1 表达与 TTR（复发时间）改善显着相关，但对 OS（总生存期）没有显着影响。在 Kaplan-Meier 分析中，食管腺癌中 IFITM1 的表达对 TTR 或 OS 没有影响，但在调整后的 Cox 回归中，IFITM1 表达对 TTR（HR 3.05，95% CI 1.09-8.53）和 OS（HR 2.71，95% CI 1.11-6.67）都有负面影响。 IFITM1 在胃食管腺癌中过度表达并与 M0 疾病相关。在胃癌中，IFITM1 表达对 TTR 有积极影响，但在食管癌中，它似乎对生存产生不利影响。 IFITM1 对食管癌和胃癌的不同预后影响的原因尚不清楚，需要进一步研究。本文的在线版本 (doi:10.1186/s40364-016-0064-5) 包含补充材料，可供授权用户使用。
There is an increasing amount of reports on IFITM1 (interferon-inducible transmembrane protein 1) in various malignancies. The aim of this study was to examine the expression of IFITM1 and its prognostic significance in gastroesophageal adenocarcinoma. Tissue samples were obtained from a consecutive cohort of 174 patients surgically treated between 2006 and 2010 for gastroesophageal (gastric, gastroesophageal junction and esophageal) adenocarcinoma, not subjected to neoadjuvant therapy. Expression of IFITM1 was examined using immunohistochemistry on tissue microarrays of primary tumors and paired samples of adjacent normal epithelium, intestinal metaplasia and lymph node metastases. Expression of IFITM1 was significantly elevated in primary tumors and lymph node metastases compared to adjacent normal epithelium and intestinal metaplasia, regardless of tumor location. Overexpression of IFITM1 was associated with M0-disease (no distant metastases). In gastric cancer IFITM1 expression was significantly associated with improved TTR (time to recurrence) in Kaplan-Meier analysis and Cox regression, both in the unadjusted analysis (HR 0.33, 95 % CI 0.12-0.88) and in the adjusted analysis (HR 0.32, 95 % CI 0.12-0.87) but there was no significant impact on OS (overall survival). In esophageal adenocarcinoma expression of IFITM1 had no impact on TTR or OS in Kaplan-Meier-analyses, but in the adjusted Cox regression IFITM1 expression had a negative impact on both TTR (HR 3.05, 95 % CI 1.09-8.53) and OS (HR 2.71, 95 % CI 1.11-6.67). IFITM1 was overexpressed in gastroesophageal adenocarcinoma and associated with M0-disease. In gastric cancer IFITM1 expression had a positive impact on TTR but in esophageal cancer it seemed to have an adverse impact on survival. The reason for the diverging prognostic impact of IFITM1 in esophageal and gastric cancer is unclear and warrants further studies. The online version of this article (doi:10.1186/s40364-016-0064-5) contains supplementary material, which is available to authorized users.